Why the study?
Dysglycemia is common in patients with AF-related acute ischemic stroke, yet the prognostic relevance of acute versus chronic glycemic status in anticoagulated patients remained unclear.
Cohort (n=623)
In anticoagulated patients with AF-related acute ischemic stroke, elevated baseline fasting plasma glucose independently predicts short- and long-term adverse clinical outcomes regardless of chronic glycemic status (HbA1c).
Answers are grounded in this paper and cite their sources.
Acute glycemic markers may refine prognosis in anticoagulated AF-AIS; leaves open whether they should guide management or trials.
BackgroundDysglycemia is common in patients with atrial fibrillation (AF)-related acute ischemic stroke (AIS), yet the prognostic relevance of acute versus chronic glycemic status in anticoagulated patients remains unclear.MethodsConsecutive patients with AF-related AIS receiving anticoagulation therapy were enrolled. The endpoint was a composite of recurrent ischemic stroke, transient ischemic attack, systemic embolism, moderate-to-severe bleeding, and all-cause mortality. Multivariable Cox proportional hazards models were used to assess associations of fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) with outcomes. Restricted cubic splines explored potential nonlinear relationships. Patients were categorized by American Diabetes Association HbA1c criteria, and an FPG × HbA1c interaction was tested. Kaplan-Meier analyses illustrated cumulative event rates.ResultsAmong 623 patients, higher baseline FPG was independently associated with the composite outcome at both 90 days (hazard ratio [HR] per 1 mmol/L increase = 1.084, 95% confidence interval [CI]: 1.014-1.160) and 1 year (HR = 1.075, 95% CI: 1.016-1.136). FPG remained significantly associated with adverse outcomes at 90 days (HR = 1.101, 95% CI: 1.018-1.191) and 1 year (HR = 1.087, 95% CI: 1.019-1.159), whereas HbA1c categories showed no significant associations. No significant interaction between FPG and HbA1c was observed. Kaplan-Meier analyses demonstrated no significant differences in cumulative event rates across HbA1c-defined glycemic groups.ConclusionsElevated baseline FPG was independently associated with short- and long-term adverse outcomes in anticoagulated patients with AF-related AIS. Acute-phase glycemia may provide prognostic information complementary to HbA1c, without significant effect modification by chronic glycemic status.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cohort in Atrial fibrillation-related acute ischemic stroke (n=623). Fasting plasma glucose (FPG) per 1 mmol/L increase vs. Lower baseline FPG / American Diabetes Association HbA1c categories was evaluated on Composite of recurrent ischemic stroke, transient ischemic attack, systemic embolism, moderate-to-severe bleeding, and all-cause mortality (HR 1.084, 95% CI 1.014-1.160).
Synapse has enriched 10 related papers. Consider them for comparative context: